Celgene Corporation (CELG) Now Covered by Analysts at Sanford C. Bernstein

Sanford C. Bernstein initiated coverage on shares of Celgene Corporation (NASDAQ:CELG) in a report released on Tuesday morning. The brokerage issued an outperform rating and a $162.00 target price on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. Vetr cut shares of Celgene Corporation from a strong-buy rating to a buy rating and set a $149.76 target price on the stock. in a report on Friday, July 14th. Jefferies Group LLC reaffirmed a buy rating and issued a $160.00 target price on shares of Celgene Corporation in a report on Tuesday, July 11th. Bank of America Corporation reaffirmed a buy rating and issued a $153.00 target price on shares of Celgene Corporation in a report on Monday, July 10th. Finally, Credit Suisse Group set a $148.00 target price on shares of Celgene Corporation and gave the company a buy rating in a report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the company. Celgene Corporation currently has an average rating of Buy and a consensus target price of $151.53.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 1.14% on Tuesday, hitting $137.28. 1,064,395 shares of the stock were exchanged. The stock has a market cap of $107.40 billion, a PE ratio of 42.51 and a beta of 1.88. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17. The company’s 50 day moving average is $141.03 and its 200-day moving average is $130.15.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/18/celgene-corporation-celg-now-covered-by-analysts-at-sanford-c-bernstein.html.

In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 46,233 shares of company stock valued at $6,268,259 in the last 90 days. 0.95% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of CELG. Waldron LP grew its holdings in shares of Celgene Corporation by 48.9% during the 1st quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock worth $640,000 after purchasing an additional 1,709 shares during the period. Millie Capital Management LLC grew its holdings in shares of Celgene Corporation by 0.4% during the 1st quarter. Millie Capital Management LLC now owns 30,670 shares of the biopharmaceutical company’s stock worth $3,816,000 after purchasing an additional 136 shares during the period. Willingdon Wealth Management grew its holdings in shares of Celgene Corporation by 3.0% during the 1st quarter. Willingdon Wealth Management now owns 9,114 shares of the biopharmaceutical company’s stock worth $1,134,000 after purchasing an additional 268 shares during the period. Shaker Investments LLC OH grew its holdings in shares of Celgene Corporation by 140.3% during the 1st quarter. Shaker Investments LLC OH now owns 15,131 shares of the biopharmaceutical company’s stock worth $1,883,000 after purchasing an additional 8,835 shares during the period. Finally, Riggs Asset Managment Co. Inc. grew its holdings in shares of Celgene Corporation by 2.0% during the 1st quarter. Riggs Asset Managment Co

Other analysts have also recently issued research reports about the stock. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. Vetr cut shares of Celgene Corporation from a strong-buy rating to a buy rating and set a $149.76 target price on the stock. in a report on Friday, July 14th. Jefferies Group LLC reaffirmed a buy rating and issued a $160.00 target price on shares of Celgene Corporation in a report on Tuesday, July 11th. Bank of America Corporation reaffirmed a buy rating and issued a $153.00 target price on shares of Celgene Corporation in a report on Monday, July 10th. Finally, Credit Suisse Group set a $148.00 target price on shares of Celgene Corporation and gave the company a buy rating in a report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the company. Celgene Corporation currently has an average rating of Buy and a consensus target price of $151.53.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 1.14% on Tuesday, hitting $137.28. 1,064,395 shares of the stock were exchanged. The stock has a market cap of $107.40 billion, a PE ratio of 42.51 and a beta of 1.88. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17. The company’s 50 day moving average is $141.03 and its 200-day moving average is $130.15.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/18/celgene-corporation-celg-now-covered-by-analysts-at-sanford-c-bernstein.html.

In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 46,233 shares of company stock valued at $6,268,259 in the last 90 days. 0.95% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of CELG. Waldron LP grew its holdings in shares of Celgene Corporation by 48.9% during the 1st quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock worth $640,000 after purchasing an additional 1,709 shares during the period. Millie Capital Management LLC grew its holdings in shares of Celgene Corporation by 0.4% during the 1st quarter. Millie Capital Management LLC now owns 30,670 shares of the biopharmaceutical company’s stock worth $3,816,000 after purchasing an additional 136 shares during the period. Willingdon Wealth Management grew its holdings in shares of Celgene Corporation by 3.0% during the 1st quarter. Willingdon Wealth Management now owns 9,114 shares of the biopharmaceutical company’s stock worth $1,134,000 after purchasing an additional 268 shares during the period. Shaker Investments LLC OH grew its holdings in shares of Celgene Corporation by 140.3% during the 1st quarter. Shaker Investments LLC OH now owns 15,131 shares of the biopharmaceutical company’s stock worth $1,883,000 after purchasing an additional 8,835 shares during the period. Finally, Riggs Asset Managment Co. Inc. grew its holdings in shares of Celgene Corporation by 2.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 17,909 shares of the biopharmaceutical company’s stock worth $2,228,000 after purchasing an additional 353 shares during the period. Institutional investors and hedge funds own 79.24% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply